Raw Data for Figures 1 & 2

<p><b>Figure 1 raw data. </b>The complete western blots are shown and the areas taken for inclusion in the panels in Figure 1 are highlighted (indicated by boxes).</p> <p><b>Figure 2A and C. Raw data.</b> The complete western blots are shown and the areas taken for inclusion in the panels in Figure 2 are highlighted (indicated by boxes).</p><p><b>Figure 2B. Raw data.</b> The complete western blots are shown and the areas taken for inclusion in the panels in Fig. 2 are highlighted (indicated by boxes).</p

Raw data for Figures 1 and 2

<p><b>Figure 1 raw data. </b>The complete western blots are shown and the areas taken for inclusion in the panels in Figure 1 are highlighted (indicated by boxes).</p> <p><b>Figure 2A and C. Raw data.</b> The complete western blots are shown and the areas taken for inclusion in the panels in Figure 2 are highlighted (indicated by boxes).</p><p><b>Figure 2B. Raw data.</b> The complete western blots are shown and the areas taken for inclusion in the panels in Fig. 2 are highlighted (indicated by boxes).</p><p> </p><p> </p

Data_Sheet_1_Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis.PDF

Background and AimEurope faces an elevated risk of nonalcoholic fatty liver disease (NAFLD) among people living with HIV (PLWH), contributing to the region’s highest global burden of NAFLD. However, the prevalence of NAFLD across various European countries and regions remains unclear. This study aims to investigate the prevalence and risk factors associated with NAFLD among PLWH across European countries.MethodsA systematic search was conducted across four databases: PubMed, Embase, Web of Science, and Cochrane Library. Data on the prevalence of NAFLD, nonalcoholic steatohepatitis (NASH), and fibrosis, as well as the associated risk factors, were collected among PLWH in Europe.ResultsThirty-six studies from 13 European nations were included. The prevalence of NAFLD, NASH, and fibrosis were 42% (95%CI 37–48), 35% (95%CI 21–50) and 13% (95%CI 10–15), respectively. Male gender, BMI, waist circumference, Diabetes, hypertension, metabolic syndrome, dyslipidemia, triglycerides, HDL, LDL, ALT, AST, and years on antiretroviral therapy (ART) were found to be risk factors for NAFLD. High BMI and triglycerides were associated with NASH. Patients with high BMI and triglycerides are at increased risk of significant liver fibrosis.ConclusionThe high prevalence of NAFLD, NASH, and fibrosis among PLWH in Europe highlights the need for early screening, intervention, and increased research focus on adolescents living with HIV. Furthermore, the significant variations observed between countries and regions underscore the influence of related risk factors.</p